Monthly Archives:
November 2025

Matera M, Biagioli V, Illiceto MT, Palazzi CM, Cavecchia I, Manzi A, Lugli S, Pennazzi L, Meocci M, Pedaci FA, Bertuccioli A. Pediatric acute-onset neuropsychiatric syndromes and the gut-oral-brain axis: a narrative review of emerging microbiome-immune interactions and therapeutic perspectives. Frontiers in Immunology. 2025;16. doi:10.3389/fimmu.2025.1726630

• Narrative review examining evidence linking gut and oral microbiota to immune dysregulation in PANS/PANDAS.Summarizes literature describing microbiome-related mechanisms including immune activation, increased intestinal permeability, and blood–brain barrier disruption.

• Discusses how microbial metabolites and inflammatory signaling may influence neuroinflammation and neuropsychiatric symptoms.

Thomas T, Eyre M, Ferrarin E, Newlove-Delgado T, Sie A, Armangue T, Ben-Pazi H, Benrhouma H, Clavenna A, Cardoso F, Dure LS, Jones HF, Gilbert DL, Gulati S, Jiang Y, Krajnc N, Mohammad SS, Orsini A, Sharma S, Swedo SE, Webb R, Wilmshurst JM, Yaramis A, Yilmaz S, Zuberi SM, Morton M, Dale RC, Nosadini M, Lim M. Evaluation, diagnosis, and treatment of Sydenham chorea: consensus guidelines. Pediatrics. 2025;156(6):e2025072466. doi:10.1542/peds.2025-072466

• Developed through a Delphi consensus process involving 27 international experts across neurology, psychiatry, and patient representation. Generated 88 consensus recommendations for evaluation, diagnosis, and management of children with Sydenham chorea.

• Emphasizes identification of core clinical features, including chorea and hypotonia, and screening for neuropsychiatric, cognitive, speech, swallowing, and mobility impairments.

• Recommends assessment for acute rheumatic fever features, including carditis, with etiologic evaluation tailored to regional risk.

• Supports antibiotic treatment at first presentation and long-term secondary prophylaxis per guidelines.

• Recommends corticosteroids for moderate to severe disease and IVIG or plasma exchange for inadequate recovery.

• Stresses the importance of patient, family, and school support to reduce academic and social impact.

PANDAS and PANS: Pathophysiology, Diagnostics and Therapeutic Approaches in Pediatric Autoimmune Neuropsychiatric Disorders – a literature review. March 2025. Journal of Education Health and Sport 79:57830. DOI:10.12775/JEHS.2025.79.57830

• Identifies a subgroup of children with PANS characterized by the triad of PANS symptoms, joint complaints, and family history of autoimmunity (including psoriasis).

• Suggests this subgroup may be at increased risk for inflammatory bowel disease and other immune-mediated disorders. Recommends a low threshold for evaluation of gastrointestinal inflammation using biomarkers such as hemoglobin, CRP, fecal calprotectin, and endoscopy when indicated.

• Reports that PANS symptoms may improve with effective treatment of inflammatory bowel disease.

• Notes high prevalence of joint complaints and autoimmune family history, suggesting shared immune mechanisms with psoriasis and arthritis.

Rahman SS, Hussein N, Galfrè SG, et al. Sex-associated and disease state-dependent monocyte polarization and CNS-trafficking phenotypes in pediatric acute-onset neuropsychiatric syndrome (PANS). Journal of Neuroinflammation. 2025;22:273.doi:10.1186/s12974-025-03549-6

• Characterized circulating monocyte subsets in pediatric PANS during flare and recovery states.

• Identified increased inflammatory M1-like monocytes and monocyte-derived dendritic cells during flare, with anti-inflammatory M2-like monocytes enriched during recovery.

• Described a monocyte subset with CNS-homing phenotype that was reduced during flare and restored during recovery; this subset was present in CSF in new-onset cases but absent in persistent disease.

• Authors suggest monocyte polarization and trafficking patterns vary with disease state and may relate to CNS involvement in PANS.

• Study Overview: Large population-based analysis of >56,000 Finnish adolescents in mental health services who received antibiotics.
• Key Finding: Doxycycline use linked to 30–35% lower risk of developing schizophrenia in adulthood vs. other antibiotics.
• Mechanism: May reduce brain inflammation and moderate excessive synaptic pruning, a process tied to schizophrenia.
• Implications: Suggests repurposing doxycycline as potential early preventive intervention for high-risk youth; needs clinical trials to confirm.